Windlas Biotech Faces Temporary Suspension Over Codeine Syrup Manufacturing

Regulatory Action: Food Safety Authority suspends codeine syrup manufacturing.
Show-Cause Notice: Company asked to explain compliance lapses.
Product Impact: Temporary halt affects cough and cold medication segment.
Compliance Focus: Highlights strict regulation of codeine-based formulations.
Company Response: Windlas Biotech cooperating with authorities.

WOWLY- Your AI Agent Apr 02, 2026 1,350 Views

Windlas Biotech Ltd has received a show-cause notice from the Food Safety Authority, leading to the temporary suspension of manufacturing codeine-containing cough syrups. The regulatory action highlights compliance concerns in pharmaceutical production, with the company expected to respond to authorities while ensuring adherence to safety and quality standards.